CurrentEndo
Get Weekly

Topic · page 8 of 12

Lipids & metabolic liver disease

Lipid disorders and metabolic dysfunction-associated steatotic (fatty) liver disease, as published in the endocrine journals

Briefs 281–320 of 460 placed here, newest publication first

Briefs in Lipids & metabolic liver disease

Newest publication first

  1. Cardiovasc Diabetol

    Association between the triglyceride glucose-body mass index and future cardiovascular disease risk in a population with Cardiovascular-Kidney-Metabolic syndrome stage 0–3: a nationwide prospective cohort study

    Cohort study

  2. Cardiovasc Diabetol

    Association between triglyceride-glucose related indices and all-cause and cause-specific mortality in the general population: a cohort study

    Cohort study

  3. Lancet Diabetes Endocrinol

    Long-term sex differences in atherosclerotic cardiovascular disease in individuals with heterozygous familial hypercholesterolaemia in Spain: a study using data from SAFEHEART, a nationwide, multicentre, prospective cohort study

    Cohort study

  4. Diabetes Obes Metab

    Fenofibrate and risk of end‐stage renal disease: A nationwide cohort study

    Cohort study

  5. Eur J Endocrinol

    Impact of peripheral thyroid hormone balance on liver fat: insights from the NutriAct trial

    Secondary analysis

  6. Clin Endocrinol (Oxf)

    Glucose metabolism and radiodensity of abdominal adipose tissue: A 5‐year longitudinal study in a large PET cohort

    Cohort study

  7. Cardiovasc Diabetol

    Association of triglyceride glucose-related parameters with all-cause mortality and cardiovascular disease in NAFLD patients: NHANES 1999–2018

    Cross-sectional study

  8. Cardiovasc Diabetol

    The predictive value of cumulative atherogenic index of plasma (AIP) for cardiovascular outcomes: a prospective community-based cohort study

    Cohort study

  9. J Clin Endocrinol Metab

    Pleiotropic Effects of an eQTL in the CELSR2/PSRC1/SORT1 Cluster That Associates With LDL-C and Resting Metabolic Rate

    Mechanistic study

  10. Cardiovasc Diabetol

    Association of atherogenic index of plasma with cardiovascular disease mortality and all-cause mortality in the general US adult population: results from NHANES 2005–2018

    Cohort study

  11. Cardiovasc Diabetol

    Association between triglyceride glucose-waist height ratio index and cardiovascular disease in middle-aged and older Chinese individuals: a nationwide cohort study

    Cohort study

  12. Cardiovasc Diabetol

    Longitudinal economic burden of incident complications among metabolic syndrome populations

    Cohort study

  13. Cardiovasc Diabetol

    Metabolic score for insulin resistance (METS-IR) predicts all-cause and cardiovascular mortality in the general population: evidence from NHANES 2001–2018

    Cohort study

  14. Cardiovasc Diabetol

    Six-month supplementation with high dose coenzyme Q10 improves liver steatosis, endothelial, vascular and myocardial function in patients with metabolic-dysfunction associated steatotic liver disease: a randomized double-blind, placebo-controlled trial

    Randomized controlled trial

  15. Int J Obes (Lond)

    Skin carotenoid scores and metabolic syndrome in a general Japanese population: the Hisayama study

    Cross-sectional study

  16. Diabetes Obes Metab

    Greater hepatic lipid saturation is associated with impaired glycaemic regulation in men with metabolic dysfunction‐associated steatotic liver disease but is not altered by 6 weeks of exercise training

    Randomized controlled trial

  17. Cardiovasc Diabetol

    Association between triglyceride-glucose related indices and mortality among individuals with non-alcoholic fatty liver disease or metabolic dysfunction-associated steatotic liver disease

    Cohort study

  18. Lancet Diabetes Endocrinol

    Once-weekly semaglutide in people with HIV-associated lipohypertrophy: a randomised, double-blind, placebo-controlled phase 2b single-centre clinical trial

    Randomized controlled trial

  19. Cardiovasc Diabetol

    Impaired GK-GKRP interaction rather than direct GK activation worsens lipid profiles and contributes to long-term complications: a Mendelian randomization study

    Diagnostic or prognostic study

  20. Cardiovasc Diabetol

    Dual-trajectory of TyG levels and lifestyle scores and their associations with ischemic stroke in a non-diabetic population: a cohort study

    Cohort study

  21. Obesity (Silver Spring)

    Acid accumulation is associated with metabolic alterations; higher energy, fat, and protein intake; and energy expenditure

    Cross-sectional study

  22. Cardiovasc Diabetol

    Is systemic inflammation a missing link between cardiometabolic index with mortality? Evidence from a large population-based study

    Cohort study

  23. Diabetes Res Clin Pract

    Inflammation, nutrition, and biological aging: The prognostic role of Naples prognostic score in nonalcoholic fatty liver disease outcomes

    Cohort study

  24. Cardiovasc Diabetol

    Association of triglyceride-glucose index and its related parameters with atherosclerotic cardiovascular disease: evidence from a 15-year follow-up of Kailuan cohort

    Cohort study

  25. Diabetes Care

    Association of Metabolic Syndrome With Neuroimaging and Cognitive Outcomes in the UK Biobank

    Cross-sectional study

  26. Diabetes Obes Metab

    Serum bile acid profiles are associated with heart failure with preserved ejection fraction in patients with metabolic dysfunction‐associated fatty liver disease: An exploratory study

    Cross-sectional study

  27. J Clin Endocrinol Metab

    Glycodeoxycholic Acid Inhibits Primary Bile Acid Synthesis With Minor Effects on Glucose and Lipid Homeostasis in Humans

    Research article

  28. J Clin Endocrinol Metab

    Risk of Adverse Events in Anticoagulated Patients With Atrial Fibrillation and Nonalcoholic Fatty Liver Disease

    Cohort study

  29. Nat Med

    Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial

    Randomized controlled trial

  30. Cardiovasc Diabetol

    Insulin resistance assessed by estimated glucose disposal rate and risk of incident cardiovascular diseases among individuals without diabetes: findings from a nationwide, population based, prospective cohort study

    Cohort study

  31. J Clin Endocrinol Metab

    Machine Learning Reveals the Contribution of Lipoproteins to Liver Triglyceride Content and Inflammation

    Cross-sectional study

  32. Cardiovasc Diabetol

    Prognostic effect of triglyceride glucose-related parameters on all-cause and cardiovascular mortality in the United States adults with metabolic dysfunction-associated steatotic liver disease

    Cohort study

  33. Cardiovasc Diabetol

    Triglyceride-glucose index is associated with myocardial ischemia and poor prognosis in patients with ischemia and no obstructive coronary artery disease

    Cohort study

  34. Cardiovasc Diabetol

    Correlation between the triglyceride-glucose index and left ventricular global longitudinal strain in patients with chronic heart failure: a cross-sectional study

    Cross-sectional study

  35. Cardiovasc Diabetol

    Comparison of triglyceride glucose index and modified triglyceride glucose indices in prediction of cardiovascular diseases in middle aged and older Chinese adults

    Cohort study

  36. Diabetes Obes Metab

    The prognostic value of metabolic dysfunction‐associated steatotic liver disease in acute myocardial infarction: A propensity score‐matched analysis

    Cohort study

  37. Cardiovasc Diabetol

    Lipid-based insulin-resistance markers predict cardiovascular events in metabolic dysfunction associated steatotic liver disease

    Secondary analysis

  38. Cardiovasc Diabetol

    Association of triglyceride glucose index and triglyceride glucose-body mass index with sudden cardiac arrest in the general population

    Cohort study

  39. Cardiovasc Diabetol

    Circulating total and H-specific GDF15 levels are elevated in subjects with MASLD but not in hyperlipidemic but otherwise metabolically healthy subjects with obesity

    Mechanistic study

  40. Diabetes Obes Metab

    Inclisiran in individuals with diabetes or obesity: Post hoc pooled analyses of the ORION ‐9, ORION ‐10 and ORION ‐11 Phase 3 randomized trials

    Meta-analysis

All 460 Briefs in ExploreShowing Briefs 281–320 of 460, newest first